NASDAQ : CRDF
Cardiff Oncology, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.8896 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 69.21M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 69.21M |
| Enterprise Value | 35.14M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 77.80M |
| Shares Outstanding | 77.80M |
| Shares Change (YoY) | +15.77% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 3.10% |
| Owned by Institutions (%) | 24.86% |
| Float | 75.38M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 136.23 |
| Forward PS | 195.34 |
| PB Ratio | 2.30 |
| P/TBV Ratio | 2.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 69.18 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.30 |
| Quick Ratio | 3.21 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -94.08% |
| Return on Assets (ROA) | -46.73% |
| Return on Invested Capital (ROIC) | -60.88% |
| Return on Capital Employed (ROCE) | -159.30% |
| Weighted Average Cost of Capital (WACC) | 12.77% |
| Revenue Per Employee | $16,387 |
| Profits Per Employee | -$1.29M |
| Employee Count | 31 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.56 |
| 52-Week Price Change | -60.29% |
| 50-Day Moving Average | 1.08 |
| 200-Day Moving Average | 1.44 |
| Relative Strength Index (RSI) | 38.86 |
| Average Volume (20 Days) | 415,531 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.12M |
| Short Previous Month | 12.07M |
| Short % of Shares Out | 15.58% |
| Short % of Float | 16.08% |
| Short Ratio (days to cover) | 17.70 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 508,000 |
| Gross Profit | -34.82M |
| Operating Income | -42.27M |
| Pretax Income | -40.05M |
| Net Income | -40.08M |
| EBITDA | -41.92M |
| EBIT | -42.27M |
| Loss Per Share | -$0.59 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 34.52M |
| Total Debt | 457,000 |
| Net Cash | 34.06M |
| Net Cash Per Share | $0.44 |
| Equity (Book Value) | 26.53M |
| Book Value Per Share | 0.39 |
| Working Capital | 24.80M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -40.85M |
| Capital Expenditures | -62,000 |
| Depreciation & Amortization | 351,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -40.92M |
| FCF Per Share | -$0.53 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -8,320.08% |
| Pretax Margin | -7,884.06% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -15.77% |
| Shareholder Yield | n/a |
| Earnings Yield | -66.48% |
| FCF Yield | -59.12% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $6.28 |
| Price Target Difference | 606.27% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | -21.44% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Feb 20, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -11.68 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |